HS-20137 for Chinese Moderate-to-Severe Psoriasis: A Randomized, Double-Blinded, Phase 2 Study

Lin Cai; Xiaohua Wang; Litao Zhang; Guoqiang Zhang; Liming Wu; Baoqi Yang; Zudong Meng; Jihai Shi; Guangming Han; Aihua Wei; Shanshan Li; Yi Zhao; Juan Su; Nianjin Wei; Siying Liu; Ran Liu; Wei Liu; Min Fang; Xiaoqing Zhang; Jianzhong Zhang

doi:10.1007/s13555-026-01694-1

Key Points

To assess the efficacy and safety of HS-20137 for treating moderate-to-severe plaque psoriasis.
Randomized, double-blinded study design
Involved patients with moderate-to-severe plaque psoriasis
Evaluated both efficacy and safety of the treatment in a larger cohort over an extended period.
HS-20137 demonstrated significant efficacy in reducing psoriasis severity.
Safety assessments indicated manageable side effects.
Results suggest HS-20137 could be a promising treatment option for patients with moderate-to-severe psoriasis.

Implication

Phase 2 study evaluates efficacy and safety of HS-20137 in patients with psoriasis, indicating promising results.

Abstract

Introduction: HS-20137 is a novel interleukin-23 inhibitor and is suggested to be effective for the treatment of psoriasis in a phase 1b study. Our study aimed to evaluate the effcacy and safety of HS-20137 in patients with moderate-to-severe plaque psoriasis in a larger and longer phase 2 study.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Cai et al. (2026) studied this question.

synapsesocial.com/papers/69c37aa8b34aaaeb1a67c840 https://doi.org/10.1007/s13555-026-01694-1

View Full Paper

Ask AI

Bookmark

Share

HS-20137 for Chinese Moderate-to-Severe Psoriasis: A Randomized, Double-Blinded, Phase 2 Study

Key Points

Implication

Abstract

Discussion

Cite This Study

HS-20137 for Chinese Moderate-to-Severe Psoriasis: A Randomized, Double-Blinded, Phase 2 Study

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading